Previous 10 | Next 10 |
RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks Enrollment completed in the U.S. Phase 2 study evaluating opaganib's safety and initial efficacy signal in 40 hospitalized patients with severe COVID-19 pneum...
TEL AVIV, Israel and RALEIGH, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Guy Goldberg, RedHill’s Chief Business Office...
Image source: The Motley Fool. RedHill Biopharma (NASDAQ: RDHL) Q3 2020 Earnings Call Nov 12, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: RedHill Biopharma (RDHL) Q3 2020 Earnings Call Transcript
RedHill Biopharma Ltd. (RDHL) Q3 2020 Earnings Conference Call November 12, 2020 08:30 AM ET Company Participants Alexandra Okmian - Senior Business Development and Investor Relations Manager Dror Ben-Asher - Chief Executive Officer Micha Chorin - Chief Financial Officer Rick Scruggs - Chief ...
The following slide deck was published by RedHill Biopharma Ltd. in conjunction with their 2020 Q3 earnings call. For further details see: RedHill Biopharma Ltd. 2020 Q3 - Results - Earnings Call Presentation
RedHill (RDHL): Q3 GAAP EPS of -$0.05 beats by $0.11.Revenue of $20.94M (+1395.7% Y/Y) misses by $4.42M.Press Release For further details see: RedHill EPS beats by $0.11, misses on revenue
Q3/2020 net revenues of approximately $21 million , with gross profit of $10.6 million , or approximately 51% , up from $6.7 million and approximately 32% in Q2/2020 -- Strong growth for Talicia ® with approximat...
TEL AVIV, Israel and RALEIGH, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its third-quarter 2020 financial results ...
Notice of Allowance received for combination of RedHill’s novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP protection until 2036 -- Combination of opaganib and RHB-107 demonst...
H. pylori e radication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial , with antibiotic resistance a contributing factor . D espite declining efficacy, physicians are still ...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
Redhill Biopharma Ltd. Website:
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biophar...
RedHill Biopharma Terminates License Agreement for Aemcolo® PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today ...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...